Skip to main content

Table 1 Baseline characteristics of all RA patients and of subgroups of ACPA-positive and ACPA-negative patients

From: ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation

 All RA patients (n = 299)ACPA-positive RA patients (n = 158)ACPA-negative RA patients (n = 141)
Age in years, mean (SD)57 (14)54 (14)60 (14)
Female, n (%)198 (66)105 (66)93 (66)
Symptom duration in weeks, median (IQR)15 (8–32)18 (9–38)12 (5–26)
(Sub)acute symptom onset, n (%)95 (34)39 (27)56 (43)
66-SJC, median (IQR)6 (3–11)5 (2–8)8 (3–12)
68-TJC, median (IQR)9 (4–15)7 (4–13)10 (4–18)
RF positivity, n (%)183 (61)134 (85)49 (35)
ESR (mm/h), median (IQR)28 (14–41)28 (14–41)28 (11–41)
CRP (μg/mL), median (IQR)10 (3–23)8 (3–18)12 (3–30)
PTGA (0–100), median (IQR)70 (50–80)70 (45–80)70 (60–80)
DAS44, median (IQR)2.9 (2.4–3.4)2.8 (2.3–3.3)3.0 (2.5–3.7)
MBDA category
 Low (< 30), n (%)43 (14)26 (16)17 (12)
 Moderate (30–44), n (%)64 (21)35 (22)29 (21)
 High (> 44), n (%)192 (64)97 (61)95 (67)
  1. Some data were missing as follows: symptom duration n = 4, (sub)acute symptom onset n = 23, 66-SJC n = 19, 68-TJC n = 17, ESR n = 3, PTGA n = 50 , DAS44 n = 20 and CRP n = 1
  2. Symptom duration, time between symptom onset and inclusion in cohort; (sub)acute symptom onset, prompt onset of symptoms (< 1 week); SD, standard deviation; IQR, interquartile range; SJC, 66-swollen joint count; TJC, 68-tender joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PTGA, patient global assessment; DAS, disease activity score; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; RA, rheumatoid arthritis; MBDA, multi-biomarker disease activity